此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

无菌羊水滤液硬膜外注射。

2026年9月1日 更新者:Zack McCormick、University of Utah

无菌羊水滤液硬膜外注射治疗椎管狭窄引起的腰骶神经根性疼痛的 I/II 期双盲随机前瞻性研究:SAFE 试验(改善与椎管狭窄相关的疼痛和残疾治疗的安全性和结果) .

There is a large population of patients with lumbosacral radicular pain due to spinal stenosis who do not respond to physical therapy or oral medication management, yet wish to avoid spinal surgery or are simply not candidates due to medical co-morbidity. Given the natural history of lumbar spinal stenosis, these patients typically suffer from chronic pain and disability. Currently, the typical treatment for this population is serial corticosteroid injection. The efficacy of the treatment specifically for the indication of spinal stenosis is in question and is associated with both concerning chronic sequelae and the risk, although low, of catastrophic neurologic compromise. Alternatively, hAF is a promising new biologic treatment with neuro-protective and regenerative properties. Early studies demonstrate its anti-inflammatory properties, with high levels of anti-inflammatory cytokines, in addition to its ability to assist with regeneration of peripheral nerves. Furthermore, it has a favorable side-effect profile without concern for long-term sequelae or potential for neurologic compromise. The present study aims to determine if epidural injection of hAF compared to the corticosteroid dexamethasone is more effective for the treatment of lumbosacral radicular pain due to spinal stenosis, as measured by pain, disability, psychological function, oral analgesic use, and avoidance of surgery. Evidence for superiority of epidural hAF compared to dexamethasone injection would change the treatment paradigm for refractory radicular pain due to spinal stenosis. Furthermore, even if shown to be non-inferior to epidural dexamethasone, epidural hAF would be favored given its superior safety profile. Thus, this research has the potential to improve outcomes and patient safety in a very large population with chronic pain.

研究概览

详细说明

Lumbar spinal stenosis is a common cause of chronic pain and disability in older adults and is the leading reason for spinal surgery in older adults. In this condition, degenerative changes in intervertebral discs and osseous anatomy of the spine result in narrowing of the spinal canal and neuroforamen in close proximity to the traversing spinal nerve roots, causing back and radicular leg pain, paresthesias and weakness. In the absence of a progressive neurologic deficit, initial treatment of lumbosacral radicular pain includes physical therapy, activity modification, and oral neuropathic or analgesic medications. If this conservative approach fails to relieve pain, an image guided epidural steroid injection (ESI) is the second-line treatment. Surgical decompression may be a treatment option for some patients who fail conservative therapy, but it is not uniformly effective and is associated with substantial direct and indirect risks. Further, some patients are unwilling to undergo invasive surgical treatments, and in others, surgery is contraindicated due to medical co-morbidities.

Epidural steroid injections are widely used for the treatment of spinal stenosis. Over 25% of all epidural steroid injection in the Medicare population are administered for the treatment of pain associated with spinal stenosis, accounting for more than 500,000 injections per year. When performed with sterile technique and fluoroscopic-guidance, epidural spine injections of steroid are safe. However, steroid use in the epidural space is associated with rare but catastrophic sequelae including paraplegia due to spinal cord infarction. The larger size or aggregation of particulate steroids likely obstructs arteriolar blood flow to the spinal cord if inadvertently injected into radicular arteries during TFESI. In addition, epidural steroid use is associated with common immediate/short-term adverse events such as facial flushing, headache, insomnia, transient hypertension, increased blood glucose in patients with diabetes. Injections must often be repeated when administered for chronic radicular pain given a typical natural history of life-long pain associated with this condition, which increases the risk of long-term sequelae including osteoporosis, adrenal suppression, hypertension, cataracts, gastrointestinal bleeding, and immune system dysfunction among many others.

Furthermore, the injection treatment paradigm for patients with spinal stenosis has not been optimized. While transforaminal epidural steroid injection appears to be superior to both placebo saline injection and lidocaine injection at short-term to intermediate follow-up when performed for the indication of radicular pain due to acute disc herniation, the highest quality evidence to date suggests a lesser degree of efficacy for the indication of leg pain due to spinal stenosis This is particularly problematic given that radicular pain related to disc herniation is self-limited, whereas spinal-stenosis related radicular pain does not tend to improve over time. Thus, there is a large group of patients with spinal stenosis who fail to respond to physical therapy and oral medication management, yet either wish to avoid spinal surgery or are not eligible, and suffer from chronic pain and debility given the poor treatment options. Clearly, better treatments with more optimal safety and side-effect profiles compared to epidural corticosteroids must be investigated in this context.

There is therefore a critical need to identify safe and effective treatments for this common clinical condition, which would allow for improved patient function and pain relief. Amniotic Fluid (AF) is a promising new biologic treatment with neuro-protective and regenerative properties. Early after conception and until the mother's water breaks for the delivery of their infant, the fetus is bathed in amniotic fluid. AF functions as a supportive cushion to the fetus and provides a protective environment. AF is a rich source of nutrients, cytokines and growth factors that are required for fetal development and maturation. AF also contains multiple cell types with the potential to differentiate along multiple cell lineages. The protective and regenerative properties of AF are achieved via the exchange of water and solutes with surrounding tissues. This is accomplished via the utilization of different pathways during the course of a pregnancy that likely contribute to changes in the composition of AF with gestational age.

Early evidence demonstrates that concentrates of AF inhibit the development of peritonitis and accelerate defense-repair mechanisms within damaged joints, demonstrating protective biological properties. Since these early publications, more sophisticated evaluations have revealed the presence of antimicrobial, immunomodulatory, and growth-promoting activities of AF. For example, low AF antimicrobial activity is associated with a high incidence of an infectious syndromes in pregnant women. Components with antimicrobial, antiviral and antifungal activity that are present in AF include lysozyme, peroxidase, transferrin, beta-lysin, immunoglobulins and zinc-peptide complexes. Immunomodulatory properties of AF are evident from studies showing that enteral feeding of AF suppresses the pro-inflammatory responses in preterm pigs with necrotizing enterocolitis. Further, growth-promoting activities of AF are supported by both animal studies and in vitro studies, showing that AF can enhance neochondrogenesis, regenerate peripheral nerves and bone, accelerate re-epithelialization in corneas, and promote healing of human skin wounds. Some of the factors that are found in AF that may contribute to these activities include inflammatory mediators such as TNF-a, IL-6, IL8, and IL-1048 trophic factors that include EGF, IGF-1, FGF, HGF and TGF-a, and hyaluronic acid, an important factor in promoting re- epithelialization in human skin wounds.

Human AF also contains factors that appear to minimize scarring and adhesions. Ozgenel et al, describe how adhesions and scarring are reduced or eliminated in a peripheral nerve rat model. It is interesting that a fetal incision made early in gestation will heal without a scar whereas one made in late gestation heals with scar formation. Hyaluronic acid, which is found in high levels in AF, inhibits collagen synthesis. This hyaluronic acid-rich environment is due to a relative lack of hyaluronidase in AF and to the presence of hyaluronic acid-stimulating factor in AF. In a study investigating the effect of AF on proteases important to wound healing, human AF was shown to enhance collagenase activity, but to inhibit activities of hyaluronidase, elastase, and cathepsin.

研究类型

介入性

注册 (实际的)

58

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Utah
      • Salt Lake City、Utah、美国、84108
        • University of Utah Orthopaedic Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients who are ≥ 18 years old
  2. Pain in the low back and lower extremity (pain NRS >4) with buttock/leg pain > back pain.
  3. Radicular distribution of leg pain based on history and correlation with advancing imaging. Radicular pain may be fixed or claudicatory in nature.
  4. Pain resistant to a trial of conservative therapy (i.e. oral steroids, NSAIDs, opioids, muscle relaxants, physical therapy, chiropractic or other non-invasive care) for at least 3 months.
  5. Mild-moderate-severe lumbar foraminal or subarticular zone stenosis, and/or mild-moderate central canal spinal stenosis identified by MRI or CT scan according to radiologic criteria (Boden 1996).
  6. Ability to read English and complete the assessment questionnaires.
  7. Must have been 90 days since last steroid injection.

Exclusion Criteria:

  1. Patients in the opinion of the treating investigator who are unwilling or unable to comply with study procedures.
  2. Systemic infection or local infection over planned injection site.
  3. Bleeding disorder, current use of anticoagulants or anti-platelet medications.
  4. Intrinsic spinal cord lesions.
  5. History of central neurologic, cerebrovascular, demyelinating or muscular disease.
  6. Severe vascular, pulmonary or coronary artery disease that limits ambulation including recent myocardial infarction (within the last 6 months).
  7. Allergy to medications being used for injection procedures.
  8. Women who are pregnant, breastfeeding, or plan to become pregnant while participating in the study. If of child-bearing potential, unwillingness to use effective birth control while participating in the study.
  9. Cognitive deficit or motor neuron disease.
  10. Spinal instability requiring surgery.
  11. History of spinal fusion surgery
  12. Metastatic cancer.
  13. Concordant pain with internal rotation of the hip (or known hip joint pathology)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Transforaminal epidural Amniotic Fluid injection

Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7") will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position will be confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. Then 3 mL of Amniotic Fluid will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups.

Amniotic Fluid Allograft will be mixed with sterile water and injected using transforaminal approach

其他名称:
  • Sterile Amniotic Fluid Filtrate
有源比较器:Transforaminal epidural dexamethasone injection

Using fluoroscopic guidance, a lumbosacral epidural injection will be performed. 2-5cc of 1% lidocaine will be injected into the skin and subcutaneous tissue to anesthetize the skin and subcutaneous structures over the site of planned entry to the neural foramen. A 22 or 25 g Whitacre needle (3.5-7") will be used to access the epidural space using the sub-pedicular or infraneural transforaminal approach, depending on individual anatomy at the discretion of the treating physician. Needle tip position confirmed using anterior-posterior and lateral fluoroscopic views as well as with injection of a standard 1-3 mL aliquot of omnipaque 180 (Iohexol) (GE Healthcare) contrast material during live fluoroscopy to confirm epidural flow of contrast and to rule out an intravascular injection. 1 mL of dexamethasone sodium phosphate (10 mg/mL) combined with 2 mL of sterile water will be injected through the spinal needle for unilateral symptoms, for a total injection volume of 3 mL in both groups.

Dexamethasone sodium phosphate mixed with 2 mL sterile water will be injected by transforaminal approach

其他名称:
  • 地塞米松

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The Percentage of Participants Reporting >50% Improvement in the Numeric Rating Scale Pain Score at 3 Months; Back and Leg Pain Separately.
大体时间:3 months

Categorical measures of both pain and function will be used for the primary outcome analysis given recent recommendations by the National Institute of Health.

3 months

次要结果测量

结果测量
措施说明
大体时间
Mean Change in the Numeric Pain Rating Scale (NPRS) Pain Score (Back and Leg Pain Separately).
大体时间:From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

NPRS scale from 0 to 10, with 0 being no pain and 10 being worst imaginable pain

From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)
The Number of Participants Reporting >30% Improvement in the Oswestry Disability Index at 3 Months
大体时间:3 months

How many participants reported a greater than 30% improvement in the Oswestry Disability Index at 3 months.

3 months
Mean Change in Oswestry Disability Index (ODI) Score Improvement
大体时间:From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

The Oswestry Disability Index (ODI) consists of 10 questions, scored from 0-5 (minimum to maximum).

The point total from each section is summed, divided by the total points possible of all sections answered, and multiplied by 100 to create a percentage disability from 0-100%, with a lower percentage indicating less disability.

From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)
The Percentage of Participants Reporting >30% Improvement in the Swiss Spinal Stenosis Questionnaire (SSSQ) Score.
大体时间:From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

The Swiss Spinal Stenosis Questionnaire (SSSQ) used for this study is scored by summing responses across two subscales:

Symptom severity:

Questions 1-4: Assess pain in the back and lower limbs. Questions 5-7: Assess neuroischemic symptoms (numbness, weakness, balance).

Scoring:

Each question (except Q7) is scored on a 1 to 5 scale, with 1 indicating no symptoms and 5 indicating very severe symptoms.

Question 7 (balance) has three options: 1, 3, or 5. 7 Calculation: Sum the scores for questions 1-7 to get the total symptom severity score.

Physical function:

Questions 8-12: Assess walking capacity and functional limitations. Scoring: Each question is scored on a 1 to 4 scale, with higher scores indicating greater disability.

Calculation: Sum the scores for questions 8-12 to get the total functional disability score.

The scores from follow-up visits will be compared to the participant's Baseline scores to calculate improvement percentage.

From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)
Mean Change in the Swiss Spinal Stenosis Questionnaire (SSSQ) Score
大体时间:From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

Swiss Spinal Stenosis Questionnaire (SSSQ) is scored across two scales: Symptom Severity (7 Q) and Physical Function (5 Q). The Symptom Severity scale is subdivided into two domains: Pain and Neuroischemic Symptoms.

  1. Symptom Severity Scale (Q 1-7) This section evaluates pain intensity and frequency (Pain domain; Q 1-4), as well as neuroischemic symptoms such as numbness, tingling, and weakness (Neuroischemic Symptoms domain; Q 5-7).

    • Scoring Range: 1 - 5 per question, (1 = none, 5 = very severe) Highest Pain score=20 Lowest=4 / Highest Neuro=15 Lowest=3
    • Calculation: Average of answers.
    • Interpretation: A higher score indicates a greater severity of symptoms.
  2. Physical Function Scale (Q 8-12) This section measures how much symptoms restrict daily activities

    • Scoring Range: 1 - 4 per question (1 = normal activity, 4 = severe limitation) Highest score=20 / Lowest=5
    • Calculation: Average of answers
    • Interpretation: Higher score shows greater functional disability.
From the Baseline Visit to Visit 8 (24 months) or after Protocol Version 15, Baseline Visit to Visit 6 (6 months)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Zachary L McCormick, MD、University of Utah

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年6月16日

初级完成 (实际的)

2025年7月1日

研究完成 (实际的)

2025年7月1日

研究注册日期

首次提交

2020年8月28日

首先提交符合 QC 标准的

2020年8月28日

首次发布 (实际的)

2020年9月3日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月1日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅